NCT06534463Recruiting
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
The Effectiveness and Safety of Different Treatment Modalities in Real-World Clinical Practice Among Chinese Patients with Marginal Zone Lymphoma: a Prospective, Observational, Multi-center Study
Source: ClinicalTrials.gov · Last updated 3 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 21 Jul 2024
- Start date
- 2 Aug 2024
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Ruijin Hospital
- Diseases
- Childhood cancers
- NCT number
- NCT06534463
What you commit to
- Study type: Observational
- Planned participants: 500
- From 2 Aug 2024 to the primary completion date, 1 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Any reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.
Who the study is looking for
- Be diagnosed as MZL
- Meet the treatment indications for MZL
Age in the registry: 14 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Ruijin Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.